1. Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease.
- Author
-
Smyth, Laura J., Dahlström, Emma H., Syreeni, Anna, Kerr, Katie, Kilner, Jill, Doyle, Ross, Brennan, Eoin, Nair, Viji, Fermin, Damian, Nelson, Robert G., Looker, Helen C., Wooster, Christopher, Andrews, Darrell, Anderson, Kerry, McKay, Gareth J., Cole, Joanne B., Salem, Rany M., Conlon, Peter J., Kretzler, Matthias, and Hirschhorn, Joel N.
- Subjects
DIABETIC nephropathies ,METHYLATION ,DNA methylation ,TYPE 1 diabetes ,DISEASE risk factors ,KIDNEY failure ,DNA adducts ,DNA - Abstract
Type 1 diabetes affects over nine million individuals globally, with approximately 40% developing diabetic kidney disease. Emerging evidence suggests that epigenetic alterations, such as DNA methylation, are involved in diabetic kidney disease. Here we assess differences in blood-derived genome-wide DNA methylation associated with diabetic kidney disease in 1304 carefully characterised individuals with type 1 diabetes and known renal status from two cohorts in the United Kingdom-Republic of Ireland and Finland. In the meta-analysis, we identify 32 differentially methylated CpGs in diabetic kidney disease in type 1 diabetes, 18 of which are located within genes differentially expressed in kidneys or correlated with pathological traits in diabetic kidney disease. We show that methylation at 21 of the 32 CpGs predict the development of kidney failure, extending the knowledge and potentially identifying individuals at greater risk for diabetic kidney disease in type 1 diabetes. Approximately 40 percent of people with type 1 diabetes develop kidney disease, but the risk factors are not well understood. Here, the authors identify DNA methylation signatures associated with diabetic kidney disease, of which 21 biomarkers predict the development of kidney failure. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF